BR112022012641A2 - Compostos tricíclicos substituídos - Google Patents

Compostos tricíclicos substituídos

Info

Publication number
BR112022012641A2
BR112022012641A2 BR112022012641A BR112022012641A BR112022012641A2 BR 112022012641 A2 BR112022012641 A2 BR 112022012641A2 BR 112022012641 A BR112022012641 A BR 112022012641A BR 112022012641 A BR112022012641 A BR 112022012641A BR 112022012641 A2 BR112022012641 A2 BR 112022012641A2
Authority
BR
Brazil
Prior art keywords
compound
formula
tricyclic compounds
rasopathy
infectious
Prior art date
Application number
BR112022012641A
Other languages
English (en)
Inventor
Bhosale Avadhut
Limaye Rohan
Pralhad Kurhade Sanjay
Sreedharan Nair Prathap
Mahangare Sachin
Sethi Sachin
Ramprasad Shukla Manojkumar
Dattatraya Sindkhedkar Milind
P Palle Venkata
Kumar Kamboj Rajender
Phukan Samiron
Rangrao Patil Pradeep
Majid Sayyed
Phadatare Ramesh
Walke Navnath
Pachpute Vipul
Gore Balasaheb
Tambe Vikas
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112022012641A2 publication Critical patent/BR112022012641A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Abstract

COMPOSTOS TRICÍCLICOSSão SUBSTITUÍDOS. Descritos compostos de fórmula geral (I), sua forma tautomérica, seu estereo-isômero, seu sal farmaceuticamente aceitável, seu polimorfo ou seu solvato, em que o anel A, o anel B, R1 a R4, e 'n' são conforme aqui definidos, para uso como inibidores de SOS1 no tratamento de doenças ou distúrbios proliferativos, infecciosos e de RASopatia. Também são descritos métodos para sintetizar o composto de fórmula I, composições farmacêuticas contendo o composto de fórmula I, métodos para tratamento de doenças ou distúrbios proliferativos, infecciosos e de RASopatia, como por exemplo câncer, através da administração do citado composto e de combinações do composto de fórmula I com outros ingredientes ativos.
BR112022012641A 2019-12-27 2020-12-27 Compostos tricíclicos substituídos BR112022012641A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN201921054254 2019-12-27
IN201921049099 2019-12-29
IN202021022668 2020-05-29
IN202021032769 2020-07-30
IN202021035200 2020-08-14
PCT/IB2020/062462 WO2021130731A1 (en) 2019-12-27 2020-12-27 Substituted tricyclic compounds

Publications (1)

Publication Number Publication Date
BR112022012641A2 true BR112022012641A2 (pt) 2022-09-06

Family

ID=74184675

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012641A BR112022012641A2 (pt) 2019-12-27 2020-12-27 Compostos tricíclicos substituídos

Country Status (17)

Country Link
US (1) US20230119316A1 (pt)
EP (1) EP4081521A1 (pt)
JP (1) JP2023514019A (pt)
KR (1) KR20220132543A (pt)
CN (1) CN115605476A (pt)
AU (1) AU2020412429A1 (pt)
BR (1) BR112022012641A2 (pt)
CA (1) CA3165864A1 (pt)
CL (1) CL2022001739A1 (pt)
CO (1) CO2022010460A2 (pt)
CR (1) CR20220363A (pt)
EC (1) ECSP22058816A (pt)
IL (1) IL294198A (pt)
MX (1) MX2022008066A (pt)
PE (1) PE20221283A1 (pt)
WO (1) WO2021130731A1 (pt)
ZA (1) ZA202207722B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202136240A (zh) 2019-12-19 2021-10-01 美商亞文納營運公司 用於靶向降解雄激素受體之化合物及方法
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
TW202229291A (zh) * 2020-12-07 2022-08-01 大陸商北京泰德製藥股份有限公司 Ｓｏｓ１抑制劑、包含其的藥物組合物及其用途
AU2022210517A1 (en) * 2021-01-19 2023-07-27 Lupin Limited Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
CN114835719A (zh) * 2021-02-01 2022-08-02 苏州泽璟生物制药股份有限公司 取代双环并芳杂环胺类抑制剂及其制备方法和应用
AU2022250712A1 (en) 2021-03-31 2023-10-05 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
CN117479942A (zh) 2021-04-09 2024-01-30 勃林格殷格翰国际有限公司 抗癌疗法
TWI807787B (zh) * 2021-04-19 2023-07-01 大陸商昆藥集團股份有限公司 苯並嘧啶三環衍生物及製備方法和應用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN115536660A (zh) * 2021-11-04 2022-12-30 北京福元医药股份有限公司 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN116265462A (zh) * 2021-12-17 2023-06-20 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
WO2023135260A1 (en) 2022-01-14 2023-07-20 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
KR20230121208A (ko) * 2022-02-10 2023-08-18 (주)파로스아이바이오 Sos1 억제제 및 이의 유도체
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023165438A1 (zh) * 2022-03-03 2023-09-07 浙江海正药业股份有限公司 三环类衍生物及其制备方法和用途
GB202203976D0 (en) 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2148082A1 (en) * 1993-09-03 1995-03-09 Daisuke Machii Imidazoquinazoline derivatives
TW372967B (en) 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
AU2003256323A1 (en) 2002-06-26 2004-01-19 Chiron Corporation Sos1 inhibitors
US8039506B2 (en) 2006-12-20 2011-10-18 Bristol-Myers Squibb Company Bicyclic lactam factor VIIa inhibitors useful as anticoagulants
TWI434690B (zh) 2007-12-19 2014-04-21 Dainippon Sumitomo Pharma Co 雜雙環衍生物
WO2009106599A2 (en) 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
CN102633812B (zh) * 2012-04-06 2014-11-12 中国药科大学 噁唑酮并喹唑啉衍生物、制备方法及用途
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
CN106414442B (zh) 2014-04-23 2019-03-15 因赛特公司 作为BET蛋白抑制剂的1H-吡咯并[2,3-c]吡啶-7(6H)-酮和吡唑并[3,4-c]吡啶-7(6H)-酮
WO2016077793A1 (en) 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
BR112018003264A2 (pt) * 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc conjugados de aldeído e usos dos mesmos
WO2017040963A1 (en) 2015-09-03 2017-03-09 Forma Therapeutics, Inc. [6,6] fused bicyclic hdac8 inhibitors
WO2018115380A1 (en) * 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
LT3728254T (lt) 2017-12-21 2023-05-10 Boehringer Ingelheim International Gmbh Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai
US20220274979A1 (en) 2018-04-18 2022-09-01 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof

Also Published As

Publication number Publication date
CL2022001739A1 (es) 2023-03-31
US20230119316A1 (en) 2023-04-20
CN115605476A (zh) 2023-01-13
ZA202207722B (en) 2023-03-29
CO2022010460A2 (es) 2022-08-09
EP4081521A1 (en) 2022-11-02
MX2022008066A (es) 2022-08-15
CR20220363A (es) 2022-09-23
WO2021130731A1 (en) 2021-07-01
AU2020412429A1 (en) 2022-08-18
CA3165864A1 (en) 2021-07-01
IL294198A (en) 2022-08-01
KR20220132543A (ko) 2022-09-30
ECSP22058816A (es) 2022-08-31
JP2023514019A (ja) 2023-04-05
PE20221283A1 (es) 2022-09-05

Similar Documents

Publication Publication Date Title
BR112022012641A2 (pt) Compostos tricíclicos substituídos
BR112022010383A2 (pt) Compostos tricíclicos substituídos
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
BR112021024131A2 (pt) Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BR112022005674A2 (pt) Derivado de anel fundido aromático substituído e composição compreendendo o mesmo, e uso do mesmo
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
BR112018072468A2 (pt) composto para uso como um inibidor de quinase, composto ou n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero, método in vitro para inibir atividade de proteína quinase e composição farmacêutica
BR112021011325A2 (pt) Derivados de rapamicina
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
BR112022012684A2 (pt) Compostos cíclicos e métodos de uso dos mesmos
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021014458A (es) Compuestos triciclicos.
EA202191588A1 (ru) Замещенные ксантиновые производные